Participant flow

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma · Source last updated 2026-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5. * Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2 * Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.

   id

   FG000

   title

   Fludarabine, Melphalan, Bortezomib

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         54

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         54

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice